Read the Annual Meeting Abstracts Now
ASGCT Staff - April 28, 2020
Our largest collection of abstracts in Society history is now available online.
Starting today, we are proud to share our collection of abstracts for the ASGCT 23rd Annual Meeting with you. This collection is the largest we've ever had and is full of the field's latest and most innovative science. You can read it online now.
For a preview of some of the presentations to look forward to during our first-ever virtual meeting, you'll find highlights below of the abstract collection, including recipients of the Excellence in Research awards, whose abstracts will be presented as part of the Presidential Symposium and Presentation of the Top Abstracts, as well as the Clinical Trials Spotlight Symposia.
Read the ASGCT 23rd Annual Meeting Abstracts
Presentation of the Top Abstracts
Thursday, May 14, 1:15-3:15 p.m.
905. Generation of Islet-Specific Gene-Edited Regulatory T Cells (edTreg) for Restoration of Immune Tolerance in Type 1 Diabetes
Presented by Peter Cook, Ph.D., Seattle Children’s Research Institute
906. Validation and Long-Term Follow Up of CD33 Off-Targets Predicted In Vitro and In Silico Using Error-Corrected Sequencing in Rhesus Macaques
Presented by Aisha AlJanahi, NIH
907. Chemical Engineering of Therapeutic RNAs for Allele Specific Gene Silencing In Vivo
Presented by Faith Conroy, UMass Medical School
908. Chimeric Antigen Receptor T Cell Therapy and Env Boosting Enables Durable SHIV Remission in Nonhuman Primates
Presented by Blake Rust, Ph.D., Fred Hutchinson Cancer Research Center
Clinical Trials Spotlight Symposia
Friday, May 15, 8-9:45 a.m.
1298. Resolution of Sickle Cell Disease (SCD) Manifestations in Patients Treated with Lentiglobin Gene Therapy: Updated Results from the Phase 1/2 HGB-206 Group C Study
Presented by: John F. Tisdale, M.D., NHLBI, National Institutes of Health
1299. First-in-Human Gene Therapy for Tay-Sachs Disease: Report of Two Infants Treated on an Expanded Access Clinical Trial of rAAVrh8-HexA/HexB (AXO-AAV-GM2)
Presented by: Terence R. Flotte, M.D., University of Massachusetts Medical School
1300. Lentiviral Gene Therapy with Autologous Hematopoietic Stem and Progenitor Cells (HSPCs) for the Treatment of Severe Combined Immune Deficiency Due to Adenosine Deaminase Deficiency (ADA-SCID): Two Year Follow-Up Results
Presented by Donald Kohn, M.D. University of California, Los Angeles
1301. Natural Killer T Cells Expressing a GD2-CAR and IL-15 for Children with Neuroblastoma - A First-In-Human Phase 1 Trial
Presented by Andras Heczey, M.D., Baylor College of Medicine
1302. A Phase 2 Trial of MGTA-456 Cell Therapy Demonstrates Rapid and Durable Long-Term Improvement in Disease-Specific Outcomes in Inherited Metabolic Disease (IMD) Patients
Presented by John Wagner, M.D., University of Minnesota
1303. CoupledCARTMTechnology for Treating Thyroid Cancer & 1304. Novel CoupledCARTMTechnology for Treating Colorectal Cancer
Presented by Lei Xiao, Innovative Cellular Therapeutics
Related Articles